Wall Street is positive on Nabriva Therapeutics PLC - ADR (NBRV). On average, analysts give NBRV a Buy rating. The average price target is $2.675, which means analysts expect the stock to rise by 157.21% over the next twelve months. That average ranking earns NBRV an Analyst Rating of 20, which is better than 20% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating NBRV a Buy today. Find out what this means to you and get the rest of the rankings on NBRV!